Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease
news
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
Company expects to have a Data Safety and Monitoring Board (DSMB) review by the end of this year Newton, Massachusetts, May 31, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the
May 31, 2023
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body MyositisPress Releases
